CD274 and non-small cell lung carcinoma: Then, standalone immune checkpoint inhibitors targeting programmed cell death-1 (PD-1) or its ligand (PD-L1), or in combination with chemotherapy, have transformed the treatment landscape for patients with metastatic NSCLC, especially those without oncogenic driver mutations [79,80,81,82,83,84].